RemeGen Co., Ltd. (FRA:REG)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.32B +3.1% |
| Revenue (ttm) | 1.03B +286.2% |
| Net Income | 750.14M |
| EPS | 1.36 |
| Shares Out | n/a |
| PE Ratio | 5.25 |
| Forward PE | 18.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 7.16 |
| Previous Close | 7.09 |
| Day's Range | 7.16 - 7.16 |
| 52-Week Range | 7.09 - 12.79 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About RemeGen
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops p... [Read more]
News
Vor Bio announces new post hoc analysis from Phase 3 trial on telitacicept
Vor Bio (VOR) announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator, RemeGen (REGMF), evaluating telitacicept in adults with generalized myasthenia gravis.
RemeGen Earnings release: Q2 2026
RemeGen released its Q2 2026 earnings on August 24, 2026, summarizing the period's financial results.
RemeGen Quarterly report: Q2 2026
RemeGen has published its Q2 2026 quarterly earnings report on August 24, 2026.
RemeGen Earnings release: Q1 2026
RemeGen released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
RemeGen Annual report: Q4 2025
RemeGen has published its Q4 2025 annual report on March 27, 2026.
RemeGen Slides: Q4 2025
RemeGen has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 27, 2026.
RemeGen Earnings release: Q4 2025
RemeGen released its Q4 2025 earnings on March 27, 2026, summarizing the period's financial results.
AbbVie, RemeGen partner on experimental solid tumor treatment
AbbVie said on Monday it would partner with RemeGen to develop an experimental treatment for solid tumors in a deal worth up to $4.95 billion, including milestones.
RemeGen Earnings release: Q3 2025
RemeGen released its Q3 2025 earnings on October 30, 2025, summarizing the period's financial results.
RemeGen Slides: Q3 2025
RemeGen has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 30, 2025.
2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League...
RemeGen Quarterly report: Q2 2025
RemeGen has published its Q2 2025 quarterly earnings report on August 22, 2025.
RemeGen Slides: Q2 2025
RemeGen has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 22, 2025.
RemeGen Earnings release: Q2 2025
RemeGen released its Q2 2025 earnings on August 22, 2025, summarizing the period's financial results.
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agr...
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
YANTAI, China , Aug. 8, 2025 /PRNewswire/ -- On August 8 th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical t...
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset & $175M Private Placement.
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
YANTAI, China , June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan...
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
YANTAI, China , May 27, 2025 /PRNewswire/ -- On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical...
RemeGen Earnings release: Q1 2025
RemeGen released its Q1 2025 earnings on April 28, 2025, summarizing the period's financial results.
RemeGen Slides: Q1 2025
RemeGen has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on April 28, 2025.
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
YANTAI, China , April 8, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18...